KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Change in Acquisitions & Divestments (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Change in Acquisitions & Divestments for 15 consecutive years, with $39.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments fell 70.43% to $39.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $774.5 million, a 55.25% increase, with the full-year FY2025 number at $774.5 million, up 55.25% from a year prior.
  • Change in Acquisitions & Divestments was $39.3 million for Q4 2025 at Supernus Pharmaceuticals, down from $468.6 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $468.6 million in Q3 2025 to a low of $17.6 million in Q4 2022.
  • A 5-year average of $118.3 million and a median of $72.1 million in 2021 define the central range for Change in Acquisitions & Divestments.
  • Peak YoY movement for Change in Acquisitions & Divestments: plummeted 95.36% in 2022, then soared 729.88% in 2023.
  • Supernus Pharmaceuticals' Change in Acquisitions & Divestments stood at $378.0 million in 2021, then tumbled by 95.36% to $17.6 million in 2022, then skyrocketed by 102.87% to $35.6 million in 2023, then surged by 273.5% to $133.0 million in 2024, then crashed by 70.43% to $39.3 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Change in Acquisitions & Divestments are $39.3 million (Q4 2025), $468.6 million (Q3 2025), and $110.4 million (Q2 2025).